Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437600 | 0.92 | ATM (0.59) | TP53CYP2D6LMNAMAPTALDH1A1 | |
| SCHEMBL12437578 | 0.90 | MEN1 (0.55) | TP53CYP2D6ALDH1A1 | |
| SCHEMBL12437555 | 0.85 | P2RX7 (0.53) | CYP2D6LMNAMAPTP2RX7 | |
| SCHEMBL12437514 | 0.85 | HRH3 (0.67) | CYP2D6LMNAALDH1A1HRH3 | |
| SCHEMBL12437588 | 0.84 | HTT (0.62) | LMNAMAPTALDH1A1ATM | |
| SCHEMBL12437516 | 0.84 | HRH3 (0.60) | CYP2D6LMNAALDH1A1HRH3 | |
| SCHEMBL12513922 | 0.83 | ATM (0.52) | TP53LMNAMAPTTHRBATM | |
| SCHEMBL12437597 | 0.82 | CYP2D6 (0.50) | TP53CYP2D6LMNAMAPTP2RX7 | |
| SCHEMBL12437594 | 0.82 | LMNA (0.51) | TP53LMNAMAPTALDH1A1HRH3 | |
| SCHEMBL12437441 | 0.81 | PRMT5 (0.50) | TP53P2RX7ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | TP53 7/4885CYP2D6 1488/4885LMNA 2809/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | TP53 7/4885CYP2D6 1488/4885LMNA 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.